MYGN Earnings & Financial Statements
Myriad Genetics, Inc.
$4.15
+$0.07(+1.72%)
51
Overall
60
Value
50
Tech
44
Quality
Market Cap
$396.95M
Volume
1.85M
52W Range
$2.74 - $8.59
Target Price
$3.92
MYGN earnings and financial statements: Myriad Genetics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MYGN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $824.50M | $837.60M | $753.20M | $678.40M | $690.60M |
| Cost of revenue | $247.90M | $252.20M | $236.20M | - | $197.60M |
| Operating income | -$387.20M | -$123.50M | -$257.40M | -$140.60M | -$190.50M |
| EBITDA | -$323.20M | -$50.00M | -$186.10M | -$73.00M | $12.30M |
| Net income | -$365.90M | -$127.30M | -$263.30M | -$112.00M | -$27.20M |
| EPS (diluted) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $706.60M | $1.03B | $1.15B | $1.20B | $1.32B |
| Total liabilities | $338.60M | $326.50M | $363.30M | $312.90M | $352.90M |
| Shareholders’ equity | $368.00M | $701.10M | $783.20M | $885.80M | $967.80M |
| Cash and equivalents | $149.60M | $102.40M | $132.10M | $56.90M | $257.40M |
| Long-term debt | $202.90M | $127.50M | $135.90M | $130.90M | $79.30M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.80M | -$8.70M | -$110.90M | -$106.30M | $18.60M |
| Capital expenditure | -$27.40M | -$29.70M | -$73.30M | -$45.30M | -$18.00M |
| Free cash flow | -$25.60M | -$38.40M | -$184.20M | -$151.60M | $600.0K |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MYGN | $4.15 | +1.7% | 1.85M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |